局限性前列腺癌碳离子放疗、光子放疗或手术后的后续原发癌风险:倾向评分加权回顾性队列研究
该回顾性队列研究基于日本放射线医学综合研究所1580例碳离子放疗患者中1455例符合条件者,及大阪癌症登记处1983例光子放疗和5948例手术患者,采用倾向评分逆概率加权比较后续原发癌发生率。中位随访分别为7.9年、5.7年和6.0年。碳离子放疗后续原发癌风险低于光子放疗(HR 0.81,95%CI 0.66-0.99,p=0.038)和手术(HR 0.80,95%CI 0.68-0.95,p=0.0088);光子放疗高于手术(HR 1.18,95%CI 1.02-1.36,p=0.029)。
要点
- 碳离子放疗后续原发癌风险低于光子放疗(HR 0.81,95%CI 0.66-0.99)和手术(HR 0.80,95%CI 0.68-0.95)。
- 光子放疗后续原发癌风险高于手术(HR 1.18,95%CI 1.02-1.36)。
- 碳离子放疗队列中年龄71-75岁 vs ≤60岁(p=0.0021)、>75岁 vs ≤60岁(p=0.012)及吸烟(p=0.0005)与后续原发癌风险升高相关。
核心结论
- 分析提示,局限性前列腺癌患者接受碳离子放疗后的后续原发癌风险似乎低于光子放疗。
- 作者认为,尽管需要更长随访的前瞻性评估来支持这些结果,但数据支持对预期长期总生存或常规治疗后结局不佳的患者更广泛地采用碳离子放疗。
研究设计与样本
- 回顾性队列研究,审查1995年6月27日至2012年7月10日在日本放射线医学综合研究所接受碳离子放疗的前列腺癌患者记录。
- 从大阪癌症登记处检索1994年1月1日至2012年12月31日诊断和治疗的前列腺癌患者记录。
- 纳入组织学确认的局限性前列腺癌且最低随访至少3个月的患者,无年龄限制。
- 排除转移、淋巴结阳性或局部侵袭性(T4期)前列腺癌、既往或同时性恶性肿瘤、以及既往接受放疗或化疗的患者。
- 采用多变量分析和倾向评分逆概率加权回顾性比较碳离子束、光子放疗或手术治疗的局限性前列腺癌患者的后续原发癌发生率。
主要发现
- 日本放射线医学综合研究所1580例接受碳离子放疗的前列腺癌患者中,1455例(92%)符合纳入标准。
- 大阪登记处38594例前列腺癌患者中,纳入1983例(5%)接受光子放疗和5948例(15%)接受手术的患者。
- 中位随访时间:碳离子放疗患者7.9年(IQR 5.9-10.0,数据库限制为最大10年随访后),光子放疗患者5.7年(4.5-6.4),手术患者6.0年(5.0-8.6)。
- 碳离子放疗队列诊断234例后续原发癌,部分患者发生多个肿瘤。
- 多变量分析中,年龄(71-75岁 vs ≤60岁,p=0.0021;>75岁 vs ≤60岁,p=0.012)和吸烟(p=0.0005)与碳离子放疗患者后续原发癌风险升高相关。
关键数值与推荐
- 倾向评分加权分析中,碳离子放疗后续原发癌风险低于光子放疗(HR 0.81,95%CI 0.66-0.99;p=0.038)。
- 碳离子放疗后续原发癌风险低于手术(HR 0.80,95%CI 0.68-0.95;p=0.0088)。
- 光子放疗后续原发癌风险高于手术(HR 1.18,95%CI 1.02-1.36;p=0.029)。
临床怎么用
- 作者认为,数据支持对预期长期总生存或常规治疗后结局不佳的患者更广泛地采用碳离子放疗。
- 作者指出,需要更长随访的前瞻性评估来支持这些结果。
局限性
- 需要更长随访的前瞻性评估来支持这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of subsequent primary cancers in patients with prostate cancer after treatment with photon radiotherapy is small in absolute numbers, but it is higher than that after surgical treatment. Carbon ion radiotherapy has a theoretically lower risk of inducing secondary malignancies than photon radiotherapy, but this risk has not been investigated in practice because of the low number of facilities offering such therapy worldwide and the limited data on long-term follow-up because the therapy has only been available since 1994. We aimed to analyse the risk of subsequent primary cancers after treatment with carbon ion radiotherapy in patients with localised prostate cancer and to compare it with that after photon radiotherapy or surgery in this setting. METHODS: In this retrospective cohort study, we reviewed records of patients who received carbon ion radiotherapy for prostate cancer between June 27, 1995, and July 10, 2012, at the National Institute of Radiological Sciences (NIRS) in Japan. We also retrieved the records of patients diagnosed and treated for prostate cancer between Jan 1, 1994, and Dec 31, 2012, from the Osaka Cancer Registry. Eligible patients had histologically confirmed localised prostate cancer and a minimum follow-up of at least 3 months; no age restrictions were applied. We excluded patients with metastasis, node-positive disease, or locally invasive (T4 stage) prostate cancer, those with previous or synchronous malignancies, and those who received previous radiotherapy or chemotherapy. We did a multivariable analysis to estimate predictors of subsequent cancers after carbon ion radiotherapy treatment. We also used propensity score inverse probability weighting to retrospectively compare the incidence of subsequent cancers in patients with localised prostate cancer treated with carbon beams, photon radiotherapy, or surgery. FINDINGS: Of 1580 patients who received carbon radiotherapy for prostate cancer at the NIRS, 1455 (92%) patients met the eligibility criteria. Of 38 594 patients with prostate cancer identified in the Osaka registry, 1983 (5%) patients treated with photon radiotherapy and 5948 (15%) treated with surgery were included. Median follow-up durations were 7·9 years (IQR 5·9-10·0) for patients who received carbon ion radiotherapy (after limiting the database to 10-year maximum follow-up), 5·7 years (4·5-6·4) for patients who received photon radiotherapy, and 6·0 years (5·0-8·6) for those who received surgery. 234 subsequent primary cancers were diagnosed in the carbon ion radiotherapy cohort; some patients developed several tumours. On multivariable analysis, age (p=0·0021 for 71-75 years vs ≤60 years; p=0·012 for >75 years vs ≤60 years) and smoking (p=0·0005) were associated with a higher risk of subsequent primary cancers in patients treated with carbon ion radiotherapy. In the propensity score-weighted analyses, carbon ion radiotherapy was associated with a lower risk of subsequent primary cancers than photon radiotherapy (hazard ratio [HR] 0·81 [95% CI 0·66-0·99]; p=0·038) or surgery (HR 0·80 [0·68-0·95]; p=0·0088), whereas photon radiotherapy was associated with a higher risk of subsequent primary cancers than surgery (HR 1·18 [1·02-1·36]; p=0·029). INTERPRETATION: Our analysis suggests that patients with localised prostate cancer treated with carbon ion radiotherapy appear to have a lower risk of subsequent primary cancers than those treated with photon radiotherapy. Although prospective evaluation with longer follow-up is warranted to support these results, our data supports a wider adoption of carbon ion radiotherapy for patients with expected long-term overall survival or those with poor outcomes after receiving conventional treatments. FUNDING: Research Project for Heavy Ions at the National Institute of Radiological Sciences (Japan).
引用
- Mohamad O, Tabuchi T, Nitta Y, et al. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study. Lancet Oncol. 2019. PMID: 30885458. doi:10.1016/S1470-2045(18)30931-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。